How have MYCOF shares performed in 2024?

Mydecine Innovations Group's stock was trading at $0.0149 on January 1st, 2024. Since then, MYCOF stock has increased by 14.1% and is now trading at $0.0170. View the best growth stocks for 2024 here .

Are investors shorting Mydecine Innovations Group?

Mydecine Innovations Group saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a drop of 99.0% from the February 29th total of 9,900 shares. Based on an average daily volume of 37,700 shares, the short-interest ratio is currently 0.0 days. View Mydecine Innovations Group's Short Interest .

How were Mydecine Innovations Group's earnings last quarter?

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) released its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.50.

When did Mydecine Innovations Group's stock split?

Mydecine Innovations Group shares reverse split on Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Mydecine Innovations Group?

Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:MYCOF

Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free MYCOF Stock Alerts

$0.02

+0.01 (+142.86%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.0170
▼
$0.0170
50-Day Range: $0.00
▼
$0.02
52-Week Range: $0.00
▼
$0.55

Volume: 237 shs
Average Volume: 24,573 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Headlines Short Interest

Get Mydecine Innovations Group alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Mydecine Innovations Group Stock (OTCMKTS:MYCOF)

Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

MYCOF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MYCOF Stock News Headlines

April 9, 2024 | uk.finance.yahoo.com

Mydecine Innovations Group Inc - SHARE FOR DEBT SETTLEMENT

March 28, 2024 | uk.finance.yahoo.com

Mydecine Innovations Group Inc - Mydecine Innovations Group Inc. Announces Closing of Share for Debt Settlement

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 20, 2024 | finance.yahoo.com

Mydecine Innovations Group Inc. Announces Share for Debt Settlement

February 7, 2024 | finance.yahoo.com

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

February 2, 2024 | finance.yahoo.com

Mydecine Innovations Group Announces Director Resignation

December 18, 2023 | uk.finance.yahoo.com

Mydecine Innovations Group Inc - Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

December 18, 2023 | finance.yahoo.com

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

November 29, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Announces Update Regarding the Special Access Program

November 28, 2023 | finance.yahoo.com

Mydecine Announces Update Regarding the Special Access Program

November 17, 2023 | finance.yahoo.com

Canadian Securities Exchange Reports October 2023 Performance Figures

October 31, 2023 | finance.yahoo.com

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

October 26, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Provides Q4 2023 Business Update

October 26, 2023 | financialpost.com

Mydecine Provides Q4 2023 Business Update

October 25, 2023 | lse.co.uk

Mydecine Innovations Group Inc Share Price (MYIG.PL)

October 16, 2023 | proactiveinvestors.com

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

October 13, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc - Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

October 12, 2023 | benzinga.com

Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market

October 12, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

October 12, 2023 | finance.yahoo.com

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

October 5, 2023 | finance.yahoo.com

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

September 28, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

September 19, 2023 | finance.yahoo.com

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

August 31, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Announces Conditional Approval of CSE Listing

August 30, 2023 | finance.yahoo.com

Mydecine Announces Conditional Approval of CSE Listing

August 15, 2023 | finanznachrichten.de

Mydecine Innovations Group Inc.: Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

See More Headlines

Receive MYCOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/16/2021
Today: 4/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:MYCOF
CUSIP: N/A
CIK: N/A
Web: www.mydecine.com
Phone: (604) 687-2038
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. David Joshua Bartch (Age 36)
Co-Founder, CEO, President & Chairman of the Board
Comp: $327.28k
Mr. Robert Roscow M.A.
Co-Founder, Chief Scientific Officer & Director
Mr. Damon Michaels
Co-Founder & COO
Mr. John Charles Ross CA (Age 66)
CPA, M.B.A., CFO & Corporate Secretary
Comp: $6.77k
Mr. Sanford M. Stein
Chief Compliance Officer & General Counsel
Dr. Rakesh Jetly FRCPC
M.D., Chief Medical Officer
Morgan Kervitsky
Director of Marketing
Mr. Michel Rudolphie
President of the European Operations
Mr. William Cook
Interim CEO & Technical Director of Mindleap Health Inc.

Key Competitors

View All Competitors

MYCOF Stock Analysis - Frequently Asked Questions

How have MYCOF shares performed in 2024?: Mydecine Innovations Group's stock was trading at $0.0149 on January 1st, 2024. Since then, MYCOF stock has increased by 14.1% and is now trading at $0.0170.
View the best growth stocks for 2024 here.
Are investors shorting Mydecine Innovations Group?: Mydecine Innovations Group saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a drop of 99.0% from the February 29th total of 9,900 shares. Based on an average daily volume of 37,700 shares, the short-interest ratio is currently 0.0 days.
View Mydecine Innovations Group's Short Interest.
How were Mydecine Innovations Group's earnings last quarter?: Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) released its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.50.

When did Mydecine Innovations Group's stock split?: Mydecine Innovations Group shares reverse split on Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of Mydecine Innovations Group?: Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MYCOF) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial